Emmanuel Laffitte
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Emmanuel Laffitte has a total of 125 co-authors. Here are the top co-authors by number of shared publications:
A. Audemard
2 shared publicationsA. Dompmartin
2 shared publications- A. Encinas Madrazo2 shared publications
A.M. Skaria
2 shared publications- Aimilios Lallas
Aristotle University of Thessaloniki Thessaloniki Greece
2 shared publications - Alessandro Borghi
Section of Dermatology and Infectious Diseases, Department of Medical Sciences, University of Ferrara, Ferrara, Italy
2 shared publications
Latest Publications
- 19 February 2026
- Published by S. Karger AG in Dermatology
- Vol. 242 (3) , 341-358
Swiss S1 Guidelines for the Management of Hidradenitis Suppurativa
Hidradenitis suppurativa (HS) is a chronic, inflammatory skin condition characterized by painful nodules, abscesses, and sinus tracts, causing significant physical and psychological distress. The profound impact of HS underscores the need for comprehensive management strategies to enhance patient outcomes and quality of life. This S1 guideline, developed by the Swiss HS Foundation, provides evidence-based recommendations for systemic and surgical treatments in HS, emphasizing the importance of standardized care practices. It incorporates insights and an informal expert consensus of Swiss dermatologists and dermatosurgeons. The guideline addresses conventional therapies, such as antibiotics and retinoids, as well as emerging biological treatments and surgical interventions, offering a holistic approach to managing this challenging disease.
- 19 February 2026
- Published by S. Karger AG in Dermatology
- Vol. 242 (3) , 341-358
Swiss S1 Guidelines for the Management of Hidradenitis Suppurativa
Hidradenitis suppurativa (HS) is a chronic, inflammatory skin condition characterized by painful nodules, abscesses, and sinus tracts, causing significant physical and psychological distress. The profound impact of HS underscores the need for comprehensive management strategies to enhance patient outcomes and quality of life. This S1 guideline, developed by the Swiss HS Foundation, provides evidence-based recommendations for systemic and surgical treatments in HS, emphasizing the importance of standardized care practices. It incorporates insights and an informal expert consensus of Swiss dermatologists and dermatosurgeons. The guideline addresses conventional therapies, such as antibiotics and retinoids, as well as emerging biological treatments and surgical interventions, offering a holistic approach to managing this challenging disease.
- 3 June 2025
- Published by S. Karger AG in European Neurology
- Vol. 88 (2) , 52-63
Small Fiber Neuropathy in Long COVID: A Cohort Study with Multimodal Assessment and Follow-Up
Introduction: Given the increasing number of patients suffering from pain associated with dysautonomic symptoms following severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection, we aimed to estimate the occurrence of small fiber neuropathy (SFN) in a cohort of long coronavirus disease 19 (COVID-19) patients reporting postinfectious neuropathic pain. Methods: The study cohort included 18 patients suffering from neuropathic pain (neuropathic pain score DN4 ≥4) appearing after or during SARS-CoV-2 infection and lasting ≥90 days; presenting normal nerve conduction studies excluding large fiber damage. Patients underwent multimodal SFN evaluation by skin biopsy, quantitative sensory testing (QST), laser evoked potential (LEP) recording and electrochemical skin conductance (ESC; Sudoscan). Results: Out of 18 patients, 17 were analyzed. Participants’ ages averaged 44 ± 9 years, with 94% females. Fourteen (82%) had abnormal skin biopsy results. Notably, 12/17 (70%) patients presented with autonomic complaints, all of whom had abnormal skin biopsy results. At 6-month follow-up, 10/17 patients reported a subjective improvement in pain and/or dysautonomia with or without symptomatic pharmacological or non-pharmacological treatment. In our cohort, QST showed the highest sensibility (79%) and specificity (67%), followed by LEP (sensibility 71%, specificity 67%). ESC showed poor reliability in the screening of SFN with a sensibility of 7% and specificity of 50%. Conclusion: The results of our study suggest that SFN may develop during or shortly after SARS-CoV-2 infection, provoking disabling sensory and dysautonomic symptoms that tend to persist for more than 6 months. Furthermore, our findings imply that noninvasive exams are a useful complement to biopsy in the diagnostic process of SFN.
- 3 June 2025
- Published by S. Karger AG in European Neurology
- Vol. 88 (2) , 52-63
Small Fiber Neuropathy in Long COVID: A Cohort Study with Multimodal Assessment and Follow-Up
Introduction: Given the increasing number of patients suffering from pain associated with dysautonomic symptoms following severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection, we aimed to estimate the occurrence of small fiber neuropathy (SFN) in a cohort of long coronavirus disease 19 (COVID-19) patients reporting postinfectious neuropathic pain. Methods: The study cohort included 18 patients suffering from neuropathic pain (neuropathic pain score DN4 ≥4) appearing after or during SARS-CoV-2 infection and lasting ≥90 days; presenting normal nerve conduction studies excluding large fiber damage. Patients underwent multimodal SFN evaluation by skin biopsy, quantitative sensory testing (QST), laser evoked potential (LEP) recording and electrochemical skin conductance (ESC; Sudoscan). Results: Out of 18 patients, 17 were analyzed. Participants’ ages averaged 44 ± 9 years, with 94% females. Fourteen (82%) had abnormal skin biopsy results. Notably, 12/17 (70%) patients presented with autonomic complaints, all of whom had abnormal skin biopsy results. At 6-month follow-up, 10/17 patients reported a subjective improvement in pain and/or dysautonomia with or without symptomatic pharmacological or non-pharmacological treatment. In our cohort, QST showed the highest sensibility (79%) and specificity (67%), followed by LEP (sensibility 71%, specificity 67%). ESC showed poor reliability in the screening of SFN with a sensibility of 7% and specificity of 50%. Conclusion: The results of our study suggest that SFN may develop during or shortly after SARS-CoV-2 infection, provoking disabling sensory and dysautonomic symptoms that tend to persist for more than 6 months. Furthermore, our findings imply that noninvasive exams are a useful complement to biopsy in the diagnostic process of SFN.
- 17 August 2024
- Published by Elsevier in Annales de Dermatologie et de Vénéréologie
- Vol. 151 (3) , 103303
Successful treatment of resistant lichen planopilaris with topical tofacitinib monotherapy
- 17 August 2024
- Published by Elsevier in Annales de Dermatologie et de Vénéréologie
- Vol. 151 (3) , 103303
Successful treatment of resistant lichen planopilaris with topical tofacitinib monotherapy
- Open Access
- 1 January 2013
- Published by S. Karger AG in Dermatology
- Vol. 227 (2) , 189-192
Newsletter No. 30
- 1 January 2013
- Published by S. Karger AG in Dermatology
- Vol. 227 (2) , 189-192
Open AccessNewsletter No. 30
- 26 January 2006
- Published by Oxford University Press (OUP) in British Journal of Dermatology
- Vol. 154 (3) , 563
Thalidomide, semen distribution, teratogenicity… and cost
- 26 January 2006
- Published by Oxford University Press (OUP) in British Journal of Dermatology
- Vol. 154 (3) , 563
Thalidomide, semen distribution, teratogenicity… and cost